Angiodynamics Inc (ANGO) Stock Price & Analysis
Angiodynamics Inc (ANGO) rose 3.44% to USD 12.34 as of June 10, 2026 at 05:36 UTC, according to Nexqual real-time market data.
ANGO last closed at USD 11.93; the session ranged USD 11.91–12.38 on volume of 225,954 shares. Market capitalization is $509.88M, with a 52-week range of USD 8.36–13.99 (NMS). Source: Nexqual, June 10, 2026 at 05:36 UTC.
Key Statistics (as of June 10, 2026 at 05:36 UTC)
| Price | USD 12.34 |
|---|---|
| Change | ▲ 3.44% (up) |
| Previous Close | USD 11.93 |
| Open | USD 11.95 |
| Day Range | USD 11.91 – 12.38 |
| 52-Week Range | USD 8.36 – 13.99 |
| Volume | 225,954 shares |
| Market Cap | $509.88M |
| Exchange | NMS |
Technical Analysis (ANGO)
Nexqual's technical model rates ANGO "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:36 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.58 (neutral) |
| vs SMA50 | Above (USD 11.02) |
| MACD | 0.2 (positive) |
Analyst Ratings (ANGO)
Wall Street analysts rate ANGO "None" based on 4 analysts, with a mean price target of USD 18 (range USD 16–24), per Nexqual as of June 10, 2026 at 05:36 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 18 |
| High Target | USD 24 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ANGO)
| Next Earnings Date | 2026-04-02 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $80.24M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-02-28 | USD 0.02 vs est -0.11 ▲ beat |
| 2025-11-30 | USD 0 vs est -0.1 ▲ beat |
| 2025-08-31 | USD -0.1 vs est -0.12 ▲ beat |
| 2025-05-31 | USD -0.03 vs est -0.12 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:36 UTC.
Financials & Fundamentals (ANGO)
| Total Revenue | $313.72M |
|---|---|
| Revenue Growth (YoY) | +8.90% |
| Gross Margin | +54.30% |
| Operating Margin | -8.20% |
| Profit Margin | -10.01% |
| ROE | -17.47% |
| Debt / Equity | 6.57 |
| Current Ratio | 2.35 |
| Total Cash | $37.81M |
| Total Debt | $11.39M |
| Free Cash Flow | $13.94M |
Source: Nexqual, June 10, 2026 at 05:36 UTC.
Financial Health Score (ANGO)
Nexqual rates Angiodynamics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:36 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 54%, operating -8% |
| Balance Sheet | Strong — $38M cash vs $11M debt, net cash position |
| Cash Flow | Mixed — FCF $14M, slim 4.8% margin |
| Efficiency | Critical — ROE -17%, ROA -4.7% |
Ownership (ANGO)
| Insider Ownership | +12.28% |
|---|---|
| Institutional Ownership | +94.68% |
| Shares Outstanding | 41.32M |
| Float | 34.61M |
| Short % of Float | +4.86% |
Source: Nexqual, June 10, 2026 at 05:36 UTC.
Leadership (ANGO)
Angiodynamics Inc is led by James C. Clemmer (age 61), CEO, President & Director, per Nexqual as of June 10, 2026 at 05:36 UTC.
| CEO, President & Director | James C. Clemmer (age 61) |
|---|---|
| Executive VP & CFO | Stephen A. Trowbridge (age 51) |
| Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Warren G. Nighan (age 56) |
| Vice President of Communications | Saleem M. Cheeks |
| Senior Vice President of Business Development & Strategy | Benjamin H. Davis (age 61) |
Major Backers & Investors (ANGO)
Notable institutional backers of Angiodynamics Inc include Point72 Asset Management, L.P., Systematic Financial Management, L.P., Broadfin Holdings LLC, according to Nexqual as of June 10, 2026 at 05:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Point72 Asset Management, L.P. | 7.7% |
| Systematic Financial Management, L.P. | 5.94% |
| Broadfin Holdings LLC | 5.01% |
| Armistice Capital, LLC | 4.52% |
| Royce & Associates LP | 3.7% |
| Weber Capital Management LLC /ADV | 3.32% |
| Bastion Asset Management Inc. | 3.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.66% |
| Vanguard Group | 8.25% |
| State Street | 4.05% |
Source: Nexqual, June 10, 2026 at 05:36 UTC.
From Angiodynamics Inc's Latest SEC 10-K Filing (filed 2025-07-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Thrombectomy Our Thrombus Management portfolio includes the AlphaVac Mechanical Thrombectomy System, AngioVac venous drainage cannula and circuit, as well as catheter directed thrombolytic devices, including the Uni-Fuse system and the Uni-Fuse+ system.
- In December 2024, the NanoKnife System received expanded FDA 510(k) clearance for the ablation of prostate tissue which broadens treatment options for men and reinforces the system's strong safety and efficacy profile.
- By designing and manufacturing many of our products from raw materials, and assembling and testing our subassemblies and products, we believe that we are able to maintain better quality control, ensure compliance with applicable regulatory standards and our internal specifications, and limit outside access to our proprietary technology.
- As part of the PMA application review, the FDA will inspect the manufacturer's facilities for compliance with its Quality System Regulation, or QSR.
Partnerships
- AngioDynamics entered into a supply agreement with Biomerics (previously Precision Concepts) in Alajuela, Costa Rica.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRC | AtriCure, Inc. | USD 27.3 | ▲ 0.74% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| MMSI | Merit Medical Systems, Inc. | USD 67.51 | ▲ 4.7% |
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
| ICUI | ICU Medical, Inc. | USD 142 | ▲ 3.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:36 UTC. This page is informational and not investment advice.